The Food and Drug Administration approved Myqorzo, a once-daily pill containing the active ingredient aficamten, for adults with symptomatic obstructive hypertrophic cardiomyopathy, or oHCM. The approval, announced on Dec. 13, 2024, gives patients and cardiologists a second cardiac myosin inhibitor to treat a condition in which thickened heart muscle blocks blood flow out of the left ventricle. For the estimated population of adults living with this inherited disease, the new option arrives with a simpler prescribing setup than its predecessor, raising the question of whether it will reach more patients faster.
Why a second cardiac myosin inhibitor changes the treatment calculus
Until now, mavacamten, sold as Camzyos and approved in 2022, was the only cardiac myosin inhibitor available for oHCM. Mavacamten carries a Risk Evaluation and Mitigation Strategy, or REMS, program requirement. That program mandates certified pharmacies, regular echocardiograms, and enrollment verification before each prescription fill. Community cardiologists and smaller practices have cited the REMS logistics as a barrier to prescribing the drug, because the extra steps add administrative burden and can delay treatment starts.
Aficamten’s label, by contrast, does not include a REMS program. The full prescribing information published on DailyMed details once-daily dosing with echocardiogram monitoring to manage heart-failure risk, but it stops short of requiring the pharmacy-certification infrastructure that has constrained mavacamten’s rollout. That difference could translate into faster adoption at practices outside major academic medical centers, where REMS compliance teams are less common. Insurance claims data over the next 18 months will be the clearest measure of whether the simpler label actually accelerates uptake in those settings.
For patients, the practical consequence is direct. A drug that can be prescribed through standard pharmacy channels removes one layer of delay between diagnosis and treatment. Cardiologists who previously referred oHCM patients to specialized centers for mavacamten initiation may now be able to start therapy in their own offices. The FDA’s own announcement of the decision framed Myqorzo as a way to improve functional capacity and symptoms in adults with this rare inherited heart condition, reinforcing that the agency views the drug as a meaningful addition rather than a marginal alternative.
What the SEQUOIA-HCM trial showed about aficamten
The approval rests on results from the phase 3 SEQUOIA-HCM trial, a randomized, placebo-controlled study registered as NCT05186818. The trial enrolled patients with symptomatic obstructive hypertrophic cardiomyopathy and measured whether aficamten improved functional capacity and symptoms compared with placebo over 24 weeks. According to the peer-reviewed publication in The New England Journal of Medicine, aficamten produced statistically significant gains in peak oxygen uptake and symptom scores at that time point. More participants receiving aficamten improved by at least one New York Heart Association functional class than those on placebo, and the drug reduced left-ventricular outflow tract gradients, the pressure difference that causes symptoms like breathlessness and fainting during exertion.
The FDA’s own Drug Trials Snapshots for Myqorzo confirm the trial name, identifier, and demographic breakdown of participants. Those snapshots show that the trial population was predominantly White, a pattern also seen in the mavacamten trials. The agency published the snapshots to give clinicians and patients transparency about who was studied, but the limited racial and ethnic diversity leaves open questions about how well the results apply across broader populations.
The trial’s design focused on functional endpoints rather than hard outcomes like hospitalization or death. That is typical for oHCM drug development, where the relatively low short-term event rate makes mortality trials impractical without very large sample sizes and long follow-up periods. Still, it means that the strongest evidence for aficamten is about how patients feel and perform during exercise, not about whether the drug extends life. Longer-term extension studies and registry data will be important to clarify whether the improvements in gradients and symptoms translate into fewer complications over time.
Gaps in the evidence and what patients should watch for
Several questions remain unanswered by the clinical trial record. No post-marketing surveillance data yet exist for aficamten, so real-world rates of adverse events, drug interactions in patients taking multiple medications, and long-term durability of benefit are unknown. The prescribing information warns of potential drug interactions and the risk of systolic dysfunction, but primary-source evidence quantifying interaction rates in the polypharmacy patients typical of oHCM care has not been published. Patients who start Myqorzo will be among the first to reveal how the drug behaves outside the controlled environment of a trial.
Cost and access barriers are also uncharted. Cardiac myosin inhibitors are specialty-priced drugs, and neither the FDA approval documents nor the NEJM publication address out-of-pocket expenses, insurance coverage policies, or patient assistance programs. For patients considering the new treatment, the first step is a conversation with a cardiologist about whether oHCM is the confirmed diagnosis and whether a myosin inhibitor is appropriate alongside, or instead of, existing therapies such as beta-blockers, calcium-channel blockers, or septal reduction procedures. From there, insurance verification and financial counseling will determine whether Myqorzo is realistically within reach.
Because aficamten affects the heart’s contractility, patients will need regular imaging and lab monitoring to balance symptom relief against the risk of weakening the heart too much. The DailyMed label outlines echocardiograms at baseline and at intervals during dose titration. In practice, that means scheduling and attending those tests, and promptly reporting new symptoms such as dizziness, swelling, or sudden weight gain. Patients who notice unexpected side effects can also use the FDA’s online portal to report a problem with a prescription medication, adding to the safety information regulators and clinicians rely on.
Another gap involves how aficamten will fit into the broader treatment algorithm as more data emerge. Head-to-head trials against mavacamten have not been conducted, so there is no direct evidence that one drug is superior on efficacy, safety, or quality-of-life measures. For now, cardiologists will likely base their choice on individual patient characteristics, institutional familiarity, and the logistical differences between a REMS and non-REMS product. Over time, comparative effectiveness research using real-world data may clarify whether one agent offers advantages in certain subgroups.
Regulatory transparency and digital safeguards
As with other recent approvals, the Myqorzo decision highlights how much information regulators now publish for public review, from snapshots of trial demographics to detailed labeling. That transparency depends on the integrity of the government websites that host prescribing information, safety updates, and reporting tools. The Department of Health and Human Services maintains a formal vulnerability disclosure policy that invites security researchers to report technical issues they find on federal health sites. While that process is far removed from the clinical questions facing patients with oHCM, it underpins the reliability of the online resources those patients and their clinicians use to understand new treatments like Myqorzo.
For now, aficamten’s approval marks a significant shift in the therapeutic landscape for obstructive hypertrophic cardiomyopathy. The drug offers a second, potentially more accessible way to directly target the molecular mechanics of the disease, rather than just easing symptoms. Whether it fulfills that promise will depend on real-world safety, affordability, and the health system’s ability to integrate a complex new therapy into everyday cardiology practice without leaving behind the patients who might benefit most.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
